Drug news
NICE rejects Afinitor (everolimus) from the Cancer Drugs Fund as a treatment for breast cancer.-Novartis
The National Institute for Health and Care Excellence (NICE) has published guidelines rejecting from the Cancer Drugs Fund, Afinitor (everolimus) from Novartis, plus exemestane, as a cost effective treatment for postmenopausal women with advanced breast cancer that is HER 2 negative and hormone receptor positive and that has worsened or recurred. New overall survival data suggest the combination is less clinically effective originally thought.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.